Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SUMO1/sentrin Specific Protease 6 (SENP6) Peptide

SENP6 Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN983536
  • Target See all SENP6 products
    SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))
    Origin
    Human
    Source
    • 7
    Synthetic
    Application
    Blocking Peptide (BP), Western Blotting (WB)
    Characteristics
    This is a synthetic peptide designed for use in combination with anti-SENP6 antibody (Catalog #: ARP50600_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    Purification
    Purified
  • Application Notes
    Each Investigator should determine their own optimal working dilution for specific applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    Concentration
    1 mg/mL
    Buffer
    Final peptide concentration is 1 mg/mL in PBS.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target
    SENP6 (SUMO1/sentrin Specific Protease 6 (SENP6))
    Synonyms
    SSP1 Peptide, SUSP1 Peptide, 2810017C20Rik Peptide, E130319N12Rik Peptide, Susp1 Peptide, mKIAA0797 Peptide, fc83h02 Peptide, im:7148342 Peptide, wu:fc83h02 Peptide, zgc:171230 Peptide, SUMO1/sentrin specific peptidase 6 Peptide, SUMO/sentrin specific peptidase 6 Peptide, SUMO1/sentrin specific peptidase 6a Peptide, SENP6 Peptide, Senp6 Peptide, senp6a Peptide
    Background
    SENP6 is a UBL-specific protease that deconjugates SUMO1, SUMO2 and SUMO3 from targeted proteins. It does not seem to be involved in the processing of full-length SUMO proteins to their mature forms. SENP6 deconjugates SUMO1 from RXRA, leading to transcriptional activation. It may act preferentially on substrates containing 3 or more SUMO2 or SUMO3 moieties.Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1, MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA, MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM].

    Alias Symbols: FLJ11355, FLJ11887, KIAA0389, KIAA0797, SSP1, SUSP1

    Protein Interaction Partner: ARNT,SUMO1

    Protein Size: 1105
    Molecular Weight
    125 kDa
    Gene ID
    26054
    NCBI Accession
    NM_001100409, NP_001093879
    UniProt
    Q9GZR1
You are here:
Support